论文部分内容阅读
作者早期的经验表明,鞘内注射人体破伤风免疫球蛋白(TIG)治疗已有严重痉挛的破伤风患者不能降低死亡率,本文报道用此法治疗尚未发生痉挛的早期破伤风患者的结果。作者把97例轻症破伤风患者交替分配到A 组(鞘内注射 TIG)或 B 组(肌注 TIG)。49例为 A 组,48例为 B 组。两组的性别与年龄分布,感染方式和潜伏期基本相同。无一患者以往曾接受破伤风主动免疫。对所有患者给予以下治疗:肌肉松弛剂和镇静剂、抗菌素、伤口洗涤和护理以及必要时作气管切开。
The authors’ early experience shows that intrathecal human immunodeficiency virus (TIG) administration of tetanus for severe spasticity can not reduce mortality, and we report the results of this study in patients with early tetanus who have not developed spasticity. The authors alternately assigned 97 patients with mild tetanus to either group A (intrathecal TIG) or group B (intramuscularly TIG). 49 cases were in group A and 48 cases were in group B. The gender and age distribution, infection pattern and incubation period of the two groups were basically the same. No patient had previously received active tetanus immunization. All patients were given the following treatments: muscle relaxants and sedatives, antibiotics, wound washing and care, and, if necessary, tracheotomy.